Skip to main content
. Author manuscript; available in PMC: 2018 Dec 6.
Published in final edited form as: Sci Transl Med. 2010 Oct 27;2(55):55ra78. doi: 10.1126/scitranslmed.3000448

Fig. 2.

Fig. 2.

ICOS augments cytokine production by human TH17 cells. (A) IL-17F production was assessed by peripheral blood CD4+ T cells differentiated to a TH17 phenotype with TH17-polarizing conditions (IL-6, IL-1β, IL-23, neutralizing IFN-γ, and neutralizing IL-4 antibodies in serum containing TGF-β, a cytokine required for inducing TH17 differentiation) and activated with either aAPCs expressing CD86, CD80, CD70, ICOSL, OX40L, or 4-1BBL or with beads bearing antibodies to CD3 and CD28 on day 3 by ELISA. (B) IL-17F production was assessed by peripheral blood CD4+ T cells cultured with or without TH17-polarizing conditions and activated with aAPC engineered to express ICOSL or with beads bearing antibodies to CD3/ICOS on day 3. (C to G) Using ELISA or reverse transcription PCR (RT-PCR), we measured (C) IL-17F, (D) IL-17A, (E) IL-2, (F) IL-22, and (G) IL-10 secretion or expression by TH17-polarized CD4+ T cells activated with beads bearing antibodies to CD3, CD28, and/or ICOS on day 3. Representative of two experiments.